iBio, Inc. (NASDAQ:IBIO - Free Report) - HC Wainwright lowered their Q2 2027 earnings per share (EPS) estimates for shares of iBio in a research note issued on Friday, November 13th. HC Wainwright analyst A. Ghosh now expects that the company will post earnings per share of ($0.10) for the quarter, down from their previous forecast of ($0.07). HC Wainwright currently has a "Buy" rating and a $7.00 target price on the stock. The consensus estimate for iBio's current full-year earnings is ($0.35) per share. HC Wainwright also issued estimates for iBio's Q3 2027 earnings at ($0.11) EPS, Q4 2027 earnings at ($0.12) EPS, FY2027 earnings at ($0.38) EPS, FY2028 earnings at ($0.73) EPS, FY2029 earnings at ($0.65) EPS and FY2030 earnings at ($0.78) EPS.
iBio (NASDAQ:IBIO - Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.02. The company had revenue of $1.07 million for the quarter, compared to the consensus estimate of $0.03 million.
Several other research analysts have also weighed in on IBIO. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of iBio in a research report on Monday, September 21st. Wall Street Zen raised iBio from a "sell" rating to a "hold" rating in a report on Saturday. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $6.00.
Get Our Latest Stock Report on IBIO
iBio Stock Down 3.4%
IBIO stock opened at $0.71 on Tuesday. The business has a 50 day moving average price of $0.97 and a two-hundred day moving average price of $1.62. The company has a market cap of $49.79 million, a price-to-earnings ratio of -2.52 and a beta of 1.47. iBio has a twelve month low of $0.68 and a twelve month high of $3.82.
Institutional Investors Weigh In On iBio
Large investors have recently added to or reduced their stakes in the business. R Squared Ltd bought a new position in iBio during the third quarter worth $29,000. Headlands Technologies LLC increased its holdings in shares of iBio by 333.0% in the second quarter. Headlands Technologies LLC now owns 47,413 shares of the company's stock valued at $83,000 after purchasing an additional 36,463 shares during the last quarter. ADAR1 Capital Management LLC raised its position in shares of iBio by 15.9% in the first quarter. ADAR1 Capital Management LLC now owns 469,878 shares of the company's stock valued at $893,000 after purchasing an additional 64,347 shares during the period. Landscape Capital Management L.L.C. bought a new position in shares of iBio in the third quarter valued at about $105,000. Finally, Bank of America Corp DE raised its position in shares of iBio by 150.8% in the first quarter. Bank of America Corp DE now owns 290,413 shares of the company's stock valued at $552,000 after purchasing an additional 174,620 shares during the period. Institutional investors own 7.90% of the company's stock.
iBio News Summary
Investors following IBIO have been watching these news items:
- Positive Sentiment: iBio reported 28-week results for its experimental obesity antibody IBIO-610 in obese non-human primates: body weight was 2.3% lower relative to vehicle, fat measures were reduced, lean mass was generally maintained, and Activin E suppression persisted. The company also reported reduced food intake in rats with an experimental amylin candidate. These results could bolster confidence in its obesity pipeline, though they are preclinical and do not establish benefit in people. iBio preclinical data announcement
- Neutral Sentiment: HC Wainwright kept its Buy rating and $7 price target, but that endorsement came alongside lower earnings forecasts. iBio analyst coverage
- Negative Sentiment: HC Wainwright cut projected EPS across fiscal 2027–2030 and for each listed 2027 quarter, signaling expectations for deeper losses. Its FY2027 estimate moved to a loss of $0.38 per share from $0.30, while FY2028–FY2030 forecasts also worsened. This could weigh on sentiment, particularly as the company remains loss-making. iBio analyst coverage
iBio Company Profile
(
Get Free Report)
iBio, Inc. is a biotechnology company focused on using artificial intelligence and other computational tools to discover and develop therapies. Its research has included programs targeting obesity and metabolic diseases, as well as oncology. The company's current approach builds on its earlier work in biologics manufacturing. Historically, iBio used its plant-based FastPharming platform to produce proteins and antibodies for research and therapeutic development. iBio is based in the United States and has shifted its focus from plant-based biologics production toward AI-enabled drug discovery.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider iBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iBio wasn't on the list.
While iBio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.